LOL.... initiated from your Mom's basement?
You fear me because you don't know how I connect you to nearly 100 aliases and actually track and share them. And I'm no shill. That would be you my ugly friend. Your enthusiasm for destroying a company through lies and investor harassment shines through each day. There are consequences for this type of behavior lil' troll.
All statins, omega-3s and PCSK9(s?) will co-exist -- hyperlipidemia is too complex an issue in a huge population.
What about the neurocognitive adverse events?
Start here to learn more:
Maybe you're already on a PCSK9 clinical trial?? Might explain a few things??
I think many doctors don't have the time to do the proper research. Lovaza does a good job at lowering trigs. So as long as #'s going down and no real visible side effects, they just keep subscribing to patients. Especially Dr's that don't have AMRN/Kowa reps calling on them. In time, I think the word will get out about superiority of V over L and cheaper cost, and they will start switching them over. It is just taking time, something we don't have a ton of money for.
Sentiment: Strong Buy
Yes, very true. It is perplexing why Lovaza is still prescribed as much as it is. I guess it is the better labeling it has in the 200-500 indication. I can't see how the FDA can deny Vascepa, at the very least, equivalent verbiage.
Great point, plus lets not forget not only does Lovaza raise LDL levels, but oh yes, that little Afib Warning!
My understanding was that the Phase 3 trial for Lovaza was performed on patients who had baseline trigs near 800 while the Vascepa trial was done on patients with baseline trigs near 600. The higher the trig reading allows for a greater percentage decline when therapy is applied. For example, if Lovaza lowered a patient's reading from 800 to 500, that would be a 37.5% decline. If Vascepa lowered someone's reading from 600 to 400, that would be a 33.3% decline. At first glance it may appear that Lovaza might be more effective because of the percentage decline. However, when you look underneath, you see that Vascepa produced, in absolute terms, a lower trig count.
"The publication, titled, "A Retrospective Case Series of the Lipid Effects of Switching from Omega-3 Fatty Acid Ethyl Esters to Icosapent Ethyl in Hyperlipidemic Patients," was authored by Richard S. Castaldo, MD, is now available electronically through Postgraduate Medicine (available at: https://postgradmed.org/doi/10.3810/pgm.2014.05.2775) and is scheduled for print publication in the May 2014 issue. Dr. Castaldo conducted a retrospective chart review at 4 medical practice locations in Western New York of 14 treated patients who were initially diagnosed with high TG levels, or hyperlipidemia, and whose lipid parameters were measured two or more months after being switched to 4 g/day EPA-only Vascepa from 4 g/day Lovaza. The patients ranged from 45 to 79 years of age and were on their same prescription lipid-lowering background medication at the same dose throughout the studied period, with 10 patients on a statin, and 4 patients on a cholesterol absorption inhibitor. After being switched from Lovaza to Vascepa, 12 patients experienced a decrease in TG and LDL-C levels and 13 patients experienced a decrease in TC and non-HDL-C levels. Changes in high-density lipoprotein cholesterol (HDL-C) levels were also assessed, but the results were mixed, with no change in 1 patient, decreases in 9 patients, and increases in 4 patients. Dr. Castaldo's chart review also found Vascepa to be well tolerated with a safety profile consistent with that referenced in the U.S. Food and Drug Administration (FDA) approved label for Vascepa."
Isn't LOVAZA superior?
Triglyceride lowering - LOVAZA 44% (Vascepa 33%)
VLDLC lowering - LOVAZA 42% (Vascepa 29%)
Non HDL-C lowering - LOVAZA 14% (Vascepa 18%)
But Lovaza can raise LDL...
Clinicians argue whether an increase in LDL is as predictive for future heart disease risk as a decrease in HDL.Studies show that low HDL is 4-times better at predicting future risk than high LDL. Some doctors believe that LDL is “pretty much useless” in predicting risk, instead preferring to focus on the overlooked Triglyceride to HDL ratio.
Doctors do not care about the LDL changes, they prefer superior Triglyceride lowering of Lovaza and ratio.
shortfishfry? That guy is a total shill.
Shill: an accomplice of a hawker, gambler, or swindler who acts as an enthusiastic customer to entice or encourage others.
Why don't you ask the FDA. The very fact that they did rescind it and what's to see more data makes me wonder why you think that reduce is such a sure thing?
I don't trust Dr. Nissen but PCSK9 looks very exciting indeed. No more statins. No more fish oils. Daily routine free!
Investor uses Yahoo Message Boards
Authorities begin investigating Yahoo user using stock message board.
A long time board user and investor used deceptive tactics in order to gain editorial control of stock message board.
Investor caught editing, controlling and blocking messages by way of moderating to falsely portray the boards overall sentiment of a stock.
Blocking posts that do not fit with personal feelings and investment interest as opposed to blocking for TOS is in violation of SEC and U.S. law.
Yahoo servers contain multitude of months of historical proof of bias and moderating manipulation of messages suiting his investment interest.
Jail time for bonzo.
Yes, sounds like a typical brainless Amarin shareholder.
There are so many better stocks out there. Why bottom feed in the dead money pool?